Experienced in Antiphospholipid Syndrome

Jana Ullrychova

Usti Nad Labem, US, CZ 
Experienced in Antiphospholipid Syndrome
Usti Nad Labem, US, CZ 
OverviewLocationsClinical Research

Overview

Jana Ullrychova practices in Usti Nad Labem, Czech Republic. Ms. Ullrychova is rated as an Experienced expert by MediFind in the treatment of Antiphospholipid Syndrome. Her top areas of expertise are Antiphospholipid Syndrome, Multiple Myeloma, Smoldering Multiple Myeloma, and Mesenteric Venous Thrombosis.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Antiphospholipid Syndrome.

Gender
Female

Locations

Usti Nad Labem, US, Czech Republic

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A - An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Biological

10 Total Publications

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ullrychova's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile